Bristol Myers Squibb and scherzenegger cooperate in the commercialization of orencia in China
-
Last Update: 2013-06-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: China Council for the promotion of medicine June 17, 2013, bioscience company Bristol Myers Squibb and Xiansheng Pharmaceutical Group said that they have agreed to cooperate on the development and commercialization of the bioscience drug orencia in China, which is a subcutaneous injection for the treatment of rheumatoid arthritis This marks the expansion of the strategic partnership established by the two sides in 2010 The financial terms of the partnership agreement have not been disclosed According to the agreement, Xiansheng will be responsible for all the development and registration activities and expenses required for the listing of orencia hypodermic injection in China according to the pre agreed development plan The two companies will share responsibility for orencia's commercialization in China and share profits and related losses Orencia subcutaneous injection has been marketed in the United States, Europe and Japan for the treatment of rheumatoid arthritis Beatrice Caza, executive vice president of Squibb business operations, said: "if the cooperation is successful, orencia subcutaneous injection can not only bring new treatment options for rheumatoid arthritis patients in China, but also become the first biological drug for Squibb to enter the Chinese market Original link: http://www.rttnews.com/2136105/bristol-myers-to-partner-with-simcere-pharma-on-orencia-sc-in-china.aspx
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
